(Q31097586)

13 October 2017

0 references

Setting the bar in phase II trials: the use of historical data for determining "go/no go" decision for definitive phase III testing (English)

1 reference

13 October 2017

phase II clinical trial

0 references

phase III clinical trial

0 references

author

Andrew Vickers

series ordinal

1

1 reference

13 October 2017

3

Howard I Scher

1 reference

13 October 2017

Vennus Ballen

2

1 reference

PMC publication ID

2529160

13 October 2017

language of work or name

English

0 references

publication date

2 February 2007

1 reference

13 October 2017

Clinical Cancer Research

1 reference

13 October 2017

13

1 reference

13 October 2017

3

1 reference

13 October 2017

972-976

1 reference

The Phase III Trial in the Era of Targeted Therapy: Unraveling the “Go or No Go” Decision

13 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2529160

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2529160

Optimal two-stage designs for phase II clinical trials

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2529160

Five-year change in statistical designs of phase II trials published in leading cancer journals.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2529160

A standardization method to adjust for the effect of patient selection in phase II clinical trials.

25 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2529160

The phase II/III transition. Toward the proof of efficacy in cancer clinical trials

25 November 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/17277252

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1158/1078-0432.CCR-06-0909

1 reference

13 October 2017

1 reference

PMC publication ID

2529160

13 October 2017

PubMed publication ID

17277252

1 reference

PMC publication ID

2529160